Glassman Robert sold $559K of PHVS
Glassman Robert sold 14,493 shares of Pharvaris N.V. (PHVS) at $38.56 ($0.56M total) on 2026-09-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction reduces insider ownership, which may be interpreted as a bearish cue by short‑term traders.
Market read
Primary source insider sale; modest relevance for traders monitoring PHVS.
What to watch
The director still holds 10,500 shares, indicating continued confidence.
Background
Form 4 filings disclose insider transactions; a director sale via a pre‑arranged plan is a standard disclosure.
Ticker impact
Director Robert Glassman sold 14,493 shares for $558,812 via a 10b5-1 plan on Sep 17, reducing his stake to 10,500 shares.
Possible modest downside pressure over the next few days.
Director sales are often viewed as a bearish signal, especially when reducing holdings by ~58%.
Market effects
Minimal impact on the biotech sector; insider sales are company‑specific.
No broader regional effect.
Limited to investors tracking PHVS.
Counterpoint
The sale could be routine liquidity planning under a 10b5-1, not a negative signal.
Key entities
- CompanyPharvaris N.V.
Biotech firm listed on Nasdaq under ticker PHVS.
- InsiderRobert Glassman
Director of Pharvaris who executed the sale.
